Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial-Reference-Cited by-同舟云学术

Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial

Published:2015-05 Issue:7 Volume:51 Page:808-816
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Nishikawa Kazuhiro,Fujitani Kazumasa,Inagaki Hitoshi,Akamaru Yusuke,Tokunaga Shinya,Takagi Masakazu,Tamura Shigeyuki,Sugimoto Naotoshi,Shigematsu Tadashi,Yoshikawa Takaki,Ishiguro Tohru,Nakamura Masato,Morita Satoshi,Miyashita Yumi,Tsuburaya Akira,Sakamoto Junichi,Tsujinaka Toshimasa^ORCID

Funder

ECRIN

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer;Sasako;J Clin Oncol,2011

3. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine;Sakuramoto;N Engl J Med,2007

4. The role of chemotherapy in the current treatment of gastric cancer;Van Cutsem;Gastric Cancer,2002

5. Capecitabine and oxaliplatin for advanced esophagogastric cancer;Cunningham;N Engl J Med,2008

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials;Current Medical Research and Opinion;2024-07-13

2. Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis;Journal of Gastrointestinal Cancer;2023-05-23

3. Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer;Cureus;2023-05-10

4. Efficacy of Trastuzumab + Cisplatin Combined with Irinotecan on the Quality of Life of Patients with Advanced Her-2 Positive Gastric Cancer;Journal of Oncology;2022-08-27

5. The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data;Future Oncology;2022-07